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Introduction
The use of implantable cardioverter defibrillator (ICD) technology in humans began with large abdominal implants using epicardial patches.^ Although the therapy was shown to he extremely effective, the requiromtmt for a thoracotomy procedure to place the patch electrodes limited tho clinical applicability. As the technology advanced, more advanced pectorally implanted devices with transvenous lead systems became available,^"^ Such advancements have now led to widespread clinical use of the ICD.
It is well accepted that some biphasic wave-forms can decrease the defibrillation threshold (DFT) compared to monophasic wave forms. "^-T he shape and efficacy of biphasic waveforms can be altered by several factors including pulse amplitude, tilt, and durations. Studies in animal models and humans have demonstrated that some special biphasic waveforms can decrease DFT compared to other biphasic waveforms or a monophasic waveform,''~'* however the optimal biphasic waveform has yet to be identified in regard to pulse durations and tilt. This multicenter study evaluated a new biphasic waveform used with a new steroid eluting endocardial defibrillation lead [model 1559, Pacesetter Systems. Sylniar. CA, USA).
Patients and Methods

Patient Population
The study population included 53 successfully implanted patients. The mean age of the study population was 63.0 ± 14.7 years. There were 39 men in the group (73.6%). Mean ejection fraction was 36.8% ± 15.0% with a range of 13%-82%. There were 14 patients (26.4%) who were classified New York Heart Association (NYHA) Class I, 29 patients (54.7%) were Class II, and 9 patients (17.0%) were Class III. There were no patients identified as Class IV. In one case, data was not reported. Reported (20.8%) . combination of coronary artery disease and dilated cardiomyopathy in 9 patients (17.0%), hypertrophic cardiomyopathy in 3 patients (5.7%), valvular heart disease in 2 patients (3.8%), other cardiomyopathies in 5 patients (9.4%). and not reported in 6 patients (11.3%). In 4 patients (7.5%), an existing pacemaker system was in place. Fourteen patients (26.4%) were on amiodarone and 6 patients (11.3%) on sotalol. Twenty patients (37.8%) were taking one cardioactive drug, and 16 patients (30.2%) were taking two cardioactive drugs. There were 17 patients (32.1%) on no cardioactive drugs.
Waveform Description
The biphasic waveform was incorporated in a new implantable ICD under clinical investigation (Aegis Model 2600, Pacesetter). The waveform is produced using 95 ^iF capacitance (2 190 |xF capacitors in series). Phase 1 of the waveform has a maximal leading edge voltage of 750 V with an initial tilt of 44% (Fig. 1) . Following the 44% decay of the leading edge voltage, Phase 1 is extended another 1.6 ms before truncation. With typical shocking lead impedances, this provides a Phase 1 duration of approximately 4.5-5.0 ms. The leading edge voltage of Phase 2 is equa] to the trailing edge of Phase 1. The duration of Phase 2 is fixed at 2.5 ms.
Defibrillation Lead Description
The Model 1559 lead system is a single endocardial screw-in lead which was placed in the right ventricular (RV) apex. The tip has an extendible/retractable screw that has a stimulating surface area of 8.5 mm^. Within the helix assembly is a silicone matrix plug that incorporates 1 mg dexamethasone phosphate for gradua] steroid elution. A ring electrode for true hipolar sensing capability is positioned 1 cm proximal from the tip and has a surface area of 34 mm". Both the tip and ring electrodes are coated with a titanium nitride material to increase porosity, reduce polarization, and optimize sensing characteristics. The shocking coil is positioned 2.4 cm from the distal tip and is 5.0 cm in length. Total surface area of the shocking electrode is 459 mm^. The lead body is constructed of silicone rubber and has a diameter of 10 Fr. The two conductors for the tip and ring electrodes and the single shocking conductor are separately insulated within the lead body hy silicone rubber. The rate sensing terminal is a stan-PACE, Vol. 22 April 1999, Part Idard IS-1 connector and Ihe high voltage connector is DF-1. Lead lengths are 58. 85, and 100 cm. The ICD physical dimensions were 8.1 cm wide. 6.3 cm high, and 1.6 cm thick providing a total volume of 60 cc. The weight of the device was 110 g.
Study Design
The clinical trial included 14 participating centers in the U.S. and Europe. The study protocol required lead system electrical testing that included pacing thresholds and sensing amplitudes at implantation, predischarge from the hospital (typically the next day), and 1, 3, and B months postimplantation. Pacing and sensing values were determined hoth with external testing systems (PSA and DSA) and the ICD at the time of implantation. DFTs were measured at the time of device implantation using an external Defibrillation System Analyzer (DSA) and emulator can (Model 2670 DSA and model 2674 emulator. Pacesetter), that simulated the implanted device. The external system was used to allow control of the time from induction to shock for all patients. This provided hetter control for DFT measurements. The DFT was measured using a single step down protocol beginning at 600 V (17.1 J) and stepping down by 100 V increments. When failure to defibrillate was observed, the next test shock was increased by 50 V. The DFT was then determined hy the lowest energy test shock that resulted in successful conversion of the rhythm. If successful, conversion was observed at 4.2 J. further testing to identify the DFT was not required. Repeat testing of DFT was repeated at the 3 month follow-up at the discretion ofthe investigator and patient. This data collection was not requinjd and was therefore only collected on a subset of patients.
Statistical Analysis
A Student's paired f-test was used to compare acute and chronic DFT and sensing thresholds obtained in the "true" and "integrated" bipolar sensing configurations. A P value of < 0.05 was considered significant.
Results
All 53 patients received the model 1559 RV defibrillation lead. The lead was typically implanted on the loft side (49 patients. 92.5%) with the left sLibciavian vein predominately used (37 patients. 69.8%). The lead was inserted via the cephalic vein in the remaining 12 patients (22.6%) who had implants on the left side. Only three systems (5.7%) were implanted on the right side (1 cephalic and 2 subclavian). In one case, the venous entry was not reported. Mean capture threshold at implant using an external pacing system analyzer (PSA) was 0.7 ± 0.3 V (0.1-1.8) using a 0.5 ms pulse duration. Capture threshold was determined from the tip to the RV coil electrode as this was the configuration used by the implanted ICD for pacing. Moan pulse duration capture threshold using the DSA and implanted device was 0.065 ± 0.09 and 0.047 ± 0.005 ms. respectively, at a fixed voltage of approximately 5.4 V. As the device can be programmed to sense either "true" bipolar or "integrated" bipolar, both configurations were tested at implant. "True" hipolar use.s both the tip and anodal band electrodes for sensing (tip-ring). "Integrated"hipolaruses the tip and defihrillation coil as the electrode pair (tip-coil). The mean R wave amplitude at implant for the tip-ring configuration ranged from 14.2-9.9 mV depending on the test method (PSA. DSA. or implanted ICD). Tip-coil configuration ranged from 11.6-4.6 mV. The tip-ring configuration provided statistically higher signals for all three test systems using the paired data (Table I) .
In 48 patients (90.6%). only the RV lead was implanted with the device. In these cases, the shocking configuration was RV coil ( + ) to device can (-). In 4 patients, a second transvenous lead was required due to an elevated DFT witb the sin- 9.8 ± 6.0 4.7 ± 2.9 0.0001 DSA = detibrillation system analyzer: PSA = pacing system analyzer gle RV lead to can configuration. In three ofthe.se cases a second shocking electrode was placed in the superior vena cava (SVC), and in one case, it was placed in the coronary sinus. In the final patient, there was an existing chronic SVC lead that was therefore utilized clinically. However, the RV to can configuration alone provided acceptable thresholds in this case.
The mean DFT at implant for all shocking configurations was 9.8 ± 3.71 (4.2-17.1). The DFT was 9.4 ± 3.6 J for RV-can alone and 14.4 ± 2.2) for RV-SVC (or CS)-can. The mean first shock impedance for Ihe clinical settings was 53.5 ± 10.8 Q.
Sensing and capture thresholds on the defibrillation lead system remained stable during the chronic follow-up period. At the time of last follow-up, the R wave sensing amplitude (tip-ring) was 9.3 ± 5.4 mV (n = 42) as compared to the initial value through the implanted device of 9.9 ± 6.2 m V (n = 55). The R wave amplitude for the tipcoil configuration at last follow-up was 5.6 ± 2.2 mV (n = 3) as compared to 4.6 ± 2.8 mV (n -54) at implant. Capture threshold at last follow-up using the implanted device was 0.067 ± 0.11 ms at 5.4 V as compared to 0.047 ± 0.005 ms at 5.4 V at implant.
Twelve patients had their DFT retested at the 3 month follow-up. Eleven of these patients showed the same or lower DFT at 3 months (Fig.  2) . For the 12 patients, the mean implantation DFT was 9.8 ± 3.0 I and tbe mean DFT at the 3 month Defibrillation TfireslioTas follow-up was 7.4 ± 3.0 J. These values were shown to be statistically different (P = 0.03).
Discussion
Biphasic wavefonns can lower DFTs compared to monophasic waveforms. Development of an optimal biphasic waveform shotild address many variables including capacitance, pulse durations, tilt, and amplitude of each phase.
The new waveform described differs from conventional biphasic waveforms in three areas: capacitance value, phase 1 duration, and phase 2 duration. The capacitor value is reduced to 95 fi,F as compared to other ICD's using 125-180 ixF. This change will increase the average current in phase 1 and give a duration of the primary phase close to the chronaxie. theoretically lowering the DFT.^**"'Ŝ everal studies bave demonstrated this relationship in animals'^"^** and humans.'''"^' The phase 1 duration is defined as a moderate tilt (44%) followed by a 1.6 ms extension. This provides a hybrid approach to the fixed tilt (which may overcompensate for impedance changes) and the fixed duration (which has no compensation).''' The phase 2 duration was fixed at 2.5 ms based on the "burping" theory that the function of pbase 2 is to reduce the residual transmembrane potential from the phase 1 shock.^''•^Î n addition to sensing and pacing, the electrical performance of the ICD lead system can have an impact on the DFT. In our study, the electrical performance of the new lead system was found to be excellent during the 6 month study period. Sensing and capture thresholds remained clinically stable, possibly due to the steroid elution capability. However, a nonsteroid version ofthe lead was not prospectively compared.
Acute DFTs were found to be low and were seen to be significantly reduced at 3 months. Although the sample size in this study was small, the DFT results were favorable as compared to a larger reported study.^^ In that study of 473 patients, the mean acute DFT was 11.4 ) with a reported 3 month DFT of 9.9 J. In this limited study, the acute DFT was 9.8 J and 3 month DFT was 7.4 J. Due to the lack of randomization to other leads and waveforms in the study design, the level of contribution ofthe new waveform or new lead to the low DFT cannot be determined.
Questions regarding the sensing performance of integrated bipolar systems bave been raised before.^^"^^ In this limited study, the paired implantation data statistically revealed a reduction in the R wave amplitude for the integrated bipolar system. Tbese measurements were made during normal sinus rhythm and not following a shock. Further degradation of the signal might have been seen postshock for the integrated bipolar system.
Conclusion
It is concluded that this new hiphasic waveform provided a low acute and chronic DFT within this limited population. The sensing and pacing characteristics were also good and remained chronically stable. The steroid elution feattire may have provided this benefit, but further prospectively randomized studies are needed.
